spacer
home > ebr > Winter 2013
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2013

   
Text
PDF
bullet
BioResearch and Innovation
Cell Based Therapies

Nobels and Stem Cells


The work of Sir John Gurdon and Shinya Yamanaka was recently awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work has led Dean Griffiths at Cambridge Consultants to investigate how a major discovery can start from a minor question.
 
view
download pdf
Single-use Bioreactors

Rapid Reaction


Traditional stainless steel reactors are being overtaken by single-use bioreactors. Lee Madrid at EMD Millipore Corporation and Aurore Poles-Lahille at Millipore SAS outline the advantages that this new technology can bring.
 
view
download pdf
bullet
Discovery Technology
Cloud Computing

Up, Up and Away


Inefficient data processing often stifles innovation in research and development. Richard Heitmann at Aspera discusses the vast possibilities to be gained in new medical advancements when modern technology is used to its full potential.
 
view
download pdf
BioDevelopment
Sharing Data

Personal Medicine


In order to provide more bespoke therapeutics for cancer treatment, the industry needs to make a more conscious effort to collaborate and share patient data, says Markus Warmuth at H3 Biomedicine.
 
view
download pdf
bullet
Drug Discovery
Stem Cell Technology

Treatment from Within


Distinguishing the correct cell types in liver cell transplantation is a vital factor that contributes substantially to the success of this therapy. Eric Halioua and Etienne Marc Sokal atPromethera Biosciences explore the advantages that intrahepatic cells have over other sources.
 
view
download pdf
Differentiated Cells

iPS Power

The world of patient therapeutics can be drastically transformed through the use of in vitro differentiated cells that are derived from human induced pluripotent stem cells, Felix Haniel of Axiogenesis AG explains.
 
view
download pdf
Safety Profile

A Marked Difference


Biomarkers are an invaluable tool in drug discovery and development. Federica Crivellente and Elena Vicentini at Aptuit suggest that the use of high throughput technologies can help to generate high quality data in a more efficient and cost-effective way.
 
view
download pdf
Stem Cells in Drug Discovery

Patient in a Dish


Roberto Iacone at Roche and Blake Anson at Celluar Dynamics International examine how using improved induced pluripotent stem cell models will result in more effective medicines and help to overcome some of the challenges in this field.
 
view
download pdf
bullet
BioRegional
Biosimilars: Asian Markets

Biotech in China


James C Greenwood
at Biotechnology Industry Organization assesses the growth of the Chinese biotech industry and how investment into new products could secure their position in the drug development and manufacturing market.
 
view
download pdf
bullet
DEVELOPMENT AND PRODUCTION
Cell Line Development

Database Power


When trying to identify new cell lines, progress can be stifled by the data management process. If a more highly developed system were to be implemented, development timelines would decrease rapidly, as Eliot Randle at IDBS demonstrates.
 
view
download pdf
Diabetes Therapeutics

Crackling the Code


A promising alternative for the treatment of type 1 diabetes has been discovered. Peter Hosking at Living Cell Technologies illustrates how using encapsulated porcine insulin-producing cells significantly reduces the number of hypoglycaemic events.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

CPhI Worldwide to support International Medical Corps UK with global charity partnership


More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developerís mind set and a regulatory background in validation.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This yearís theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement